We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
UPLIZNA (Amgen Australia Pty Ltd)
Product name
UPLIZNA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
166 (175 working days)
Active ingredients
inebilizumab
Registration type
NCE/ NBE
Indication
Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive.